ACE inhibitors act to reduce hypertension by interfering with the conversion of angiotensin I to artery-constricting angiotensin II. Blocking the production of angiotensin II results in arterial vasodilation and an accompanying reduction in blood pressure. ACE inhibitors currently are recommended as first-line therapy for hypertension in certain patient populations, because of their safety and efficacy.
University of Cape Town (UCT) researchers have used cryo-electron microscopy to identify the first complete structures of the human angiotensin-converting enzyme (ACE) (cryo-EM). A protein that controls blood pressure, ACE, is essential for maintaining good heart health.
Almost half of the U.S. adult population has high blood pressure - or hypertension - and about 20% of these patients have treatment-resistant hypertension.
COVID-19 patients who also suffer from high blood pressure are more likely to fall severely ill with the disease, which also leaves them at greater risk of death.
Nearly 20% of all COVID-19-associated deaths are from cardiac complications, yet the mechanisms from which these complications arise have remained a topic of debate in the cardiology community.
An interventional therapy aimed at improving survival chances and reducing the need for critical care treatment due to COVID-19 is being investigated by physicians at The University of Texas Health Science Center at Houston.